OncoHost's PROPHETIC Study Evaluating Host Response of Late-Stage NSCLC, SCLC and Malignant Melanoma Patients Continues to Grow Ahead of U.S. Launch OncoHost,?a global leader in?next-generation precision oncology?for improved personalized cancer therapy, announced today that Roswell Park Comprehensive Cancer Center has joined its PROPHETIC study, launching a clinical site in Buffalo, New York.
The clinical trial site will use OncoHost's precision oncology platform, PROphet
